Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05552222




Registration number
NCT05552222
Ethics application status
Date submitted
21/09/2022
Date registered
23/09/2022
Date last updated
14/08/2024

Titles & IDs
Public title
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Scientific title
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
Secondary ID [1] 0 0
64007957MMY3005
Secondary ID [2] 0 0
CR109237
Universal Trial Number (UTN)
Trial acronym
MajesTEC-7
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Teclistamab
Treatment: Drugs - Daratumumab
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Talquetamab

Experimental: Teclistamab, Daratumumab SC, and Lenalidomide (Tec-DR) - Participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab and lenalidomide.

Experimental: Talquetamab, Daratumumab SC, and Lenalidomide (Tal-DR) - Participants will receive talquetamab as SC injection in combination with daratumumab and lenalidomide.

Active comparator: Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) - Participants will receive daratumumab as SC injection with lenalidomide and dexamethasone.


Treatment: Drugs: Teclistamab
Teclistamab will be administered as SC injection.

Treatment: Drugs: Daratumumab
Daratumumab will be administered as SC injection.

Treatment: Drugs: Lenalidomide
Lenalidomide will be administered orally.

Treatment: Drugs: Dexamethasone
Dexamethasone will be administered either orally or intravenously (IV).

Treatment: Drugs: Talquetamab
Talquetamab will be administered as SC injection.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
From randomization to the date of disease progression or death (Up to 09 years)
Primary outcome [2] 0 0
12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)
Timepoint [2] 0 0
At Month 12
Secondary outcome [1] 0 0
Very Good Partial Response (VGPR) or Better
Timepoint [1] 0 0
From randomization up to 09 years
Secondary outcome [2] 0 0
Complete Response (CR) or Better
Timepoint [2] 0 0
From randomization up to 09 years
Secondary outcome [3] 0 0
Sustained Minimal Residual disease (MRD)-negative Complete Response (CR)
Timepoint [3] 0 0
From randomization up to 09 years
Secondary outcome [4] 0 0
MRD-negative CR
Timepoint [4] 0 0
From randomization up to 09 years
Secondary outcome [5] 0 0
Progression Free Survival on Next-line Therapy (PFS2)
Timepoint [5] 0 0
From randomization up to 09 years
Secondary outcome [6] 0 0
Overall Survival (OS)
Timepoint [6] 0 0
From randomization to the date of death (up to 09 years)
Secondary outcome [7] 0 0
Number of Participants with Adverse Events (AEs) by Severity
Timepoint [7] 0 0
From randomization up to 09 years
Secondary outcome [8] 0 0
Number of Participants with Abnormalities in Laboratory Parameters
Timepoint [8] 0 0
From randomization up to 09 years
Secondary outcome [9] 0 0
Number of Participants with Abnormalities in Vital Signs
Timepoint [9] 0 0
From randomization up to 09 years
Secondary outcome [10] 0 0
Number of Participants with Abnormalities in Physical Examination
Timepoint [10] 0 0
From randomization up to 09 years
Secondary outcome [11] 0 0
Number of Participants with Abnormalities in Electrocardiogram (ECG)
Timepoint [11] 0 0
From randomization up to 09 years
Secondary outcome [12] 0 0
Serum Concentrations of Teclistamab and Talquetamab
Timepoint [12] 0 0
From randomization up to 09 years
Secondary outcome [13] 0 0
Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab and Talquetamab
Timepoint [13] 0 0
From randomization up to 09 years
Secondary outcome [14] 0 0
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)
Timepoint [14] 0 0
From baseline up to 9 years
Secondary outcome [15] 0 0
Change from Baseline in Treatment-related Symptoms as Assessed by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Timepoint [15] 0 0
Baseline through Cycle 6 (each cycle of 28 days) (up to 196 days)
Secondary outcome [16] 0 0
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Timepoint [16] 0 0
From baseline up to 9 years
Secondary outcome [17] 0 0
Time to Sustained Worsening in Symptoms, Functioning, and HRQoL
Timepoint [17] 0 0
From randomization up to 09 years

Eligibility
Key inclusion criteria
* Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
* Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment
* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
* A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
* A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams [mg] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (>=) 20 mg of dexamethasone within 14 days before randomization
* Had plasmapheresis within 28 days of randomization
* Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization
* Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients
* Known contraindications to the use of daratumumab or lenalidomide per local prescribing information
* Myeloma Frailty Index of >=2 with the exception of participants who have a score of 2 based on age alone

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/10/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
28/10/2033
Actual
Sample size
Target
1590
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Barwon Health - University Hospital Geelong - Geelong
Recruitment hospital [3] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [4] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [5] 0 0
Calvary Mater Newcastle Hospital - New South Wales
Recruitment hospital [6] 0 0
Wollongong Hospital - Wollongong
Recruitment hospital [7] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3220 - Geelong
Recruitment postcode(s) [3] 0 0
2170 - Liverpool
Recruitment postcode(s) [4] 0 0
6009 - Nedlands
Recruitment postcode(s) [5] 0 0
2298 - New South Wales
Recruitment postcode(s) [6] 0 0
2500 - Wollongong
Recruitment postcode(s) [7] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Linz
Country [2] 0 0
Austria
State/province [2] 0 0
Salzburg
Country [3] 0 0
Belgium
State/province [3] 0 0
Anderlecht
Country [4] 0 0
Belgium
State/province [4] 0 0
Gent
Country [5] 0 0
Belgium
State/province [5] 0 0
Haine Saint Paul La Louviere
Country [6] 0 0
Belgium
State/province [6] 0 0
Kortrijk
Country [7] 0 0
Belgium
State/province [7] 0 0
Leuven
Country [8] 0 0
Belgium
State/province [8] 0 0
Wilrijk
Country [9] 0 0
Brazil
State/province [9] 0 0
Barretos
Country [10] 0 0
Brazil
State/province [10] 0 0
Belo Horizonte
Country [11] 0 0
Brazil
State/province [11] 0 0
Curitiba
Country [12] 0 0
Brazil
State/province [12] 0 0
Fortaleza
Country [13] 0 0
Brazil
State/province [13] 0 0
Natal
Country [14] 0 0
Brazil
State/province [14] 0 0
Niteroi
Country [15] 0 0
Brazil
State/province [15] 0 0
Porto Alegre
Country [16] 0 0
Brazil
State/province [16] 0 0
Ribeirao Preto
Country [17] 0 0
Brazil
State/province [17] 0 0
Salvador
Country [18] 0 0
Brazil
State/province [18] 0 0
Sao Paulo
Country [19] 0 0
Canada
State/province [19] 0 0
Alberta
Country [20] 0 0
Canada
State/province [20] 0 0
Quebec
Country [21] 0 0
China
State/province [21] 0 0
Beijing
Country [22] 0 0
China
State/province [22] 0 0
Chang Zhou
Country [23] 0 0
China
State/province [23] 0 0
Changchun
Country [24] 0 0
China
State/province [24] 0 0
Changsha
Country [25] 0 0
China
State/province [25] 0 0
Chaoyang District
Country [26] 0 0
China
State/province [26] 0 0
Fu Zhou
Country [27] 0 0
China
State/province [27] 0 0
Guangzhou
Country [28] 0 0
China
State/province [28] 0 0
Harbin
Country [29] 0 0
China
State/province [29] 0 0
Jinan
Country [30] 0 0
China
State/province [30] 0 0
Nan Jing
Country [31] 0 0
China
State/province [31] 0 0
Nan Ning Shi
Country [32] 0 0
China
State/province [32] 0 0
Nanchang
Country [33] 0 0
China
State/province [33] 0 0
Shanghai
Country [34] 0 0
China
State/province [34] 0 0
Shenyang
Country [35] 0 0
China
State/province [35] 0 0
Tian Jin
Country [36] 0 0
China
State/province [36] 0 0
Tianjin
Country [37] 0 0
China
State/province [37] 0 0
Wenzhou
Country [38] 0 0
China
State/province [38] 0 0
WuHan
Country [39] 0 0
Czechia
State/province [39] 0 0
Brno - Bohunice
Country [40] 0 0
Czechia
State/province [40] 0 0
Hradec Kralove
Country [41] 0 0
Czechia
State/province [41] 0 0
Olomouc
Country [42] 0 0
Czechia
State/province [42] 0 0
Ostrava
Country [43] 0 0
Czechia
State/province [43] 0 0
Plzen
Country [44] 0 0
Czechia
State/province [44] 0 0
Praha
Country [45] 0 0
Denmark
State/province [45] 0 0
Vejle
Country [46] 0 0
France
State/province [46] 0 0
Creteil
Country [47] 0 0
France
State/province [47] 0 0
Lille
Country [48] 0 0
France
State/province [48] 0 0
Nantes
Country [49] 0 0
France
State/province [49] 0 0
PARIS cedex 12
Country [50] 0 0
France
State/province [50] 0 0
Pessac cedex
Country [51] 0 0
France
State/province [51] 0 0
Pierre-Benite
Country [52] 0 0
France
State/province [52] 0 0
Poitiers
Country [53] 0 0
France
State/province [53] 0 0
Rennes
Country [54] 0 0
France
State/province [54] 0 0
Strasbourg
Country [55] 0 0
France
State/province [55] 0 0
Toulouse
Country [56] 0 0
Germany
State/province [56] 0 0
Berlin
Country [57] 0 0
Germany
State/province [57] 0 0
Halle (Saale)
Country [58] 0 0
Germany
State/province [58] 0 0
Hamburg
Country [59] 0 0
Germany
State/province [59] 0 0
Nuernberg
Country [60] 0 0
Germany
State/province [60] 0 0
Tübingen
Country [61] 0 0
Germany
State/province [61] 0 0
Wurzburg
Country [62] 0 0
Greece
State/province [62] 0 0
Athens Attica
Country [63] 0 0
Greece
State/province [63] 0 0
Thessalonikis
Country [64] 0 0
Greece
State/province [64] 0 0
Thessaloniki
Country [65] 0 0
Israel
State/province [65] 0 0
Haifa
Country [66] 0 0
Israel
State/province [66] 0 0
Jerusalem
Country [67] 0 0
Israel
State/province [67] 0 0
Petah Tikva
Country [68] 0 0
Israel
State/province [68] 0 0
Ramat Gan
Country [69] 0 0
Israel
State/province [69] 0 0
Tel Aviv Yafo
Country [70] 0 0
Italy
State/province [70] 0 0
Bologna
Country [71] 0 0
Italy
State/province [71] 0 0
Firenze
Country [72] 0 0
Italy
State/province [72] 0 0
Milan
Country [73] 0 0
Italy
State/province [73] 0 0
Pavia
Country [74] 0 0
Italy
State/province [74] 0 0
Roma
Country [75] 0 0
Italy
State/province [75] 0 0
Rozzano
Country [76] 0 0
Italy
State/province [76] 0 0
Torino
Country [77] 0 0
Japan
State/province [77] 0 0
Bunkyo-Ku
Country [78] 0 0
Japan
State/province [78] 0 0
Chiba
Country [79] 0 0
Japan
State/province [79] 0 0
Higashiibaraki-gun
Country [80] 0 0
Japan
State/province [80] 0 0
Hirakata
Country [81] 0 0
Japan
State/province [81] 0 0
Hyôgo
Country [82] 0 0
Japan
State/province [82] 0 0
Iruma-gun
Country [83] 0 0
Japan
State/province [83] 0 0
Kanagawa
Country [84] 0 0
Japan
State/province [84] 0 0
Kanazawa
Country [85] 0 0
Japan
State/province [85] 0 0
Kumamoto-shi
Country [86] 0 0
Japan
State/province [86] 0 0
Matsuyama-City
Country [87] 0 0
Japan
State/province [87] 0 0
Nagasaki
Country [88] 0 0
Japan
State/province [88] 0 0
Okayama
Country [89] 0 0
Japan
State/province [89] 0 0
Osaka
Country [90] 0 0
Japan
State/province [90] 0 0
Shibukawa
Country [91] 0 0
Japan
State/province [91] 0 0
Yamagata
Country [92] 0 0
Japan
State/province [92] 0 0
Yamanashi
Country [93] 0 0
Korea, Republic of
State/province [93] 0 0
Busan
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
Goyang si
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Hwasun
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Incheon
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Seoul
Country [98] 0 0
Netherlands
State/province [98] 0 0
Amsterdam
Country [99] 0 0
Netherlands
State/province [99] 0 0
Apeldoorn
Country [100] 0 0
Netherlands
State/province [100] 0 0
Delft
Country [101] 0 0
Netherlands
State/province [101] 0 0
Nieuwegein
Country [102] 0 0
Netherlands
State/province [102] 0 0
Sittard-Geleen
Country [103] 0 0
Norway
State/province [103] 0 0
Oslo
Country [104] 0 0
Norway
State/province [104] 0 0
Trondheim
Country [105] 0 0
Poland
State/province [105] 0 0
Brzozow
Country [106] 0 0
Poland
State/province [106] 0 0
Katowice
Country [107] 0 0
Poland
State/province [107] 0 0
Kielce
Country [108] 0 0
Portugal
State/province [108] 0 0
Braga
Country [109] 0 0
Portugal
State/province [109] 0 0
Lisbon
Country [110] 0 0
Portugal
State/province [110] 0 0
Porto
Country [111] 0 0
Spain
State/province [111] 0 0
Badalona
Country [112] 0 0
Spain
State/province [112] 0 0
Barcelona
Country [113] 0 0
Spain
State/province [113] 0 0
Granada
Country [114] 0 0
Spain
State/province [114] 0 0
Jerez de la Frontera
Country [115] 0 0
Spain
State/province [115] 0 0
Madrid
Country [116] 0 0
Spain
State/province [116] 0 0
Palma de Mallorca
Country [117] 0 0
Spain
State/province [117] 0 0
Pozuelo de Alarcon
Country [118] 0 0
Spain
State/province [118] 0 0
Salamanca
Country [119] 0 0
Spain
State/province [119] 0 0
Terrassa
Country [120] 0 0
Spain
State/province [120] 0 0
Valencia
Country [121] 0 0
Sweden
State/province [121] 0 0
Falun
Country [122] 0 0
Sweden
State/province [122] 0 0
Lund
Country [123] 0 0
Sweden
State/province [123] 0 0
Stockholm
Country [124] 0 0
Sweden
State/province [124] 0 0
Örebro
Country [125] 0 0
Switzerland
State/province [125] 0 0
Bern
Country [126] 0 0
Switzerland
State/province [126] 0 0
St. Gallen
Country [127] 0 0
Turkey
State/province [127] 0 0
Ankara
Country [128] 0 0
Turkey
State/province [128] 0 0
Denizli
Country [129] 0 0
Turkey
State/province [129] 0 0
Istanbul
Country [130] 0 0
Turkey
State/province [130] 0 0
Izmir
Country [131] 0 0
Turkey
State/province [131] 0 0
Samsun
Country [132] 0 0
United Kingdom
State/province [132] 0 0
Blackpool
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Bristol
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Canterbury
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Edinburgh
Country [136] 0 0
United Kingdom
State/province [136] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Trial website
https://clinicaltrials.gov/study/NCT05552222
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05552222